Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INTERPARFUMS INCIPAR · Entity 4092 | Director | February 27, 2017 | March 01, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INTERPARFUMS INC
Report date February 27, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,500 |
Reported balance
After 2017-02-27 transaction · row 1
1 source rowRow 1 · 2017-02-27 · Exercise / conversion · Acquired 250 · Balance 2,500 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $21.76 · Expires 2018-01-31 | Direct | 0 |
Reported balance
After 2017-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-27 · Exercise / conversion · Disposed 250 · Balance 0 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $32.12 · Expires 2019-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $32.12 · Expires 2019-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $32.12 · Expires 2019-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $32.12 · Expires 2019-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $25.29 · Expires 2020-02-01 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $25.29 · Expires 2020-02-01 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $25.29 · Expires 2020-02-01 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $25.29 · Expires 2020-02-01 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2021-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2021-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2021-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2021-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2022-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2022-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2022-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 250 |
| Option-right to buySEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2022-01-31 | Direct | 250 |
Reported balance
Holding disclosure · report date 2017-02-27 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 250 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 27, 2017 Filed Mar 1, 2017 22:20 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 250 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001638599-17-000227 · doc4_4573.xml · derivative · entry 2 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:20 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionCommon Stock | 250 | $21.76 | $5,438.75 |
DisclosureSEC source: 0001638599-17-000227 · doc4_4573.xml · nonDerivative · entry 1 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:24 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 250 | $0.00 Strike: $33.95 | $0.00 |
DisclosureSEC source: 0001638599-17-000151 · doc4_4523.xml · derivative · entry 18 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 250 shares Expires 2022-01-31 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:24 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 250 | $0.00 Strike: $33.95 | $0.00 |
DisclosureSEC source: 0001638599-17-000151 · doc4_4523.xml · derivative · entry 17 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 250 shares Expires 2022-01-31 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:24 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 250 | $0.00 Strike: $33.95 | $0.00 |
DisclosureSEC source: 0001638599-17-000151 · doc4_4523.xml · derivative · entry 16 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 250 shares Expires 2022-01-31 Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:24 UTC | INTERPARFUMS INC IPAR · Entity 4092 | GrantOption-right to buy · Derivative | 250 | $0.00 Strike: $33.95 | $0.00 |
DisclosureSEC source: 0001638599-17-000151 · doc4_4523.xml · derivative · entry 15 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 250 shares Expires 2022-01-31 Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 21:55 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 250 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001638599-16-001705 · doc4_4410.xml · derivative · entry 4 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 21:55 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionOption-right to buy · Derivative | 250 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001638599-16-001705 · doc4_4410.xml · derivative · entry 3 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250 shares Expires 2017-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 21:55 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionCommon Stock | 250 | $21.76 | $5,438.75 |
DisclosureSEC source: 0001638599-16-001705 · doc4_4410.xml · nonDerivative · entry 2 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 21:55 UTC | INTERPARFUMS INC IPAR · Entity 4092 | Exercise / conversionCommon Stock | 250 | $17.07 | $4,267.50 |
DisclosureSEC source: 0001638599-16-001705 · doc4_4410.xml · nonDerivative · entry 1 LEVY JEAN · CIK 0001211778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.